Biweekly dosing of trifluridine-tipiracil reduces rates of myelosuppression while maintaining efficacy in patients with metastatic colorectal cancer
Biweekly dosing of TAS-102 demonstrated a reduction in myelosuppression, with similar PFS and OS. With an improved toxicity profile, this alternative dosing schedule may potentially broaden the utilization of TAS-102 in patients with borderline PS and provide a favorable option for future combination studies.
Authors
- Cathy Eng (ORCID: https://orcid.org/0000-0003-2335-0612)
- Christopher Cann (ORCID: https://orcid.org/0000-0002-6960-6460)
- Zhiguo Zhao (ORCID: https://orcid.org/0000-0002-7917-7268)
- Michael LaPelusa (ORCID: https://orcid.org/0000-0001-6078-0561)
- Dustin A. Deming (ORCID: https://orcid.org/0000-0003-2394-9836)
- Elizabeth Dow-Hillgartner
- Sarah K Cimino
- Victoria Cancelliere
Institutions
- Fox Chase Cancer Center (US)
- University of Wisconsin Carbone Cancer Center (US)
- Vanderbilt University Medical Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-05-01
- DOI
- https://doi.org/10.1093/oncolo/oyaf099
- Citations
- 2
- Primary Topic
- Colorectal Cancer Treatments and Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- University of Wisconsin Carbone Cancer Center